Truly hope you're right - just can't see PER being at $1.12 SP...

Truly hope you're right - just can't see PER being at $1.12 SP (based on $1B MC) in seven months without MAJOR news of a buyer, approval, results, etc.

I believe in ATL1102, and have a large stake but maybe we need to calm the horses down with SP predictions unless they are based on facts.

Things coming in 2024 for PER...

1. ATL1102 - 9 month toxicology study: final study report due mid-2024. This could lead to a US FDA Fast Track designation. This delivers a $100K approx. value to PER if we sold the fast track to another company.
## this is the possible driver of SP for this year?! ##

2. ATL1102 phase IIb clinical trial: recruitment to complete at end of March 2024. First dosing shortly after of the those recruits. 12 months from there PLUS time to collate - results collated and released. Results expected mid-2025??
## clinical trial can be monitored via disclosures such as any dropouts or negative reactions ## The longer we go without negative, the more the SP will react and anticipate.

We are cheap in my books.